



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board

Thursday, March 10, 2022, 1:00pm

DMAS -- 600 East Broad Street

Agenda

1. **Call to Order and Introductions** – John Morgan, MD, Chief Clinical Innovation Officer, Chair
2. **Minutes - Approval of Minutes from the December 1, 2021 meeting**
3. **COVID-19 Update**
4. **Service Authorization (SA) Process and Utilization Management (UM)**
 - a) PDL Class - HIV (Quantity Limits)
5. **New Drugs - Grid**
 - a) Besremi[®] (ropeginterferon alfa-2b-njft)
 - b) Livtencity[™] (maribavir)
 - c) Scemblix[®] (asciminib) *
 - d) Tavneos[™] (avacopan)
 - e) Voxzogo[™] (vosoritide)
6. **Class Criteria**
 - a) Oral Oncology – Hematologic Cancers *
7. **MRx Pipeline/DUR Quarterly Newsletter – Available on WebPortal**



COMMONWEALTH of VIRGINIA
Department of Medical Assistance Services
DRUG UTILIZATION REVIEW PROGRAM

8. Reports

- a) ProDUR
- b) RetroDUR
 - i. Recent RetroDUR Activity
 - ii. RetroDUR Criteria Estimates
 - iii. Hemoglobin A1c Lab Value Over 9 and On Diabetic Meds
- c) Utilization Analysis

9. Adjournment

DRAFT